RankAlpha logo
Back to Rankings

NVCT

NuvectisD
Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-18
View Chart
Current thesis
If NXP900's Phase 1b program begins to show biomarker-linked activity in enrolled monotherapy or EGFR-combination cohorts, NVCT could re-rate because management has described active enrollment in key Phase 1b studies and the latest confirmed financial update indicates runway through several of those milestones [#8-K-2026-02-11].
Posture
Defensive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta -0.3.
What can break
As of 2026-05-04, no verified Q1 2026 earnings release or 10-Q was available in the evidence packet, leaving surprise, guidance, and market-reaction evidence unavailable.
Momentum
100
Value
41
Sentiment
0
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $7.50 · Bull $14.00 · Bear $4.50
Data freshness
Prices
As of 2026-07-18
Fundamentals
As of 2026-07-17 • Vendor: Data Vendor v1
Scores
As of 2026-07-18 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-04 • Model: RankAlpha Sentiment Codex
Investment thesis
As of 2026-07-18
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $31.80
Why
Momentum100 · Δ7d -0.3
Value41 · Δ7d -0.1
Sentiment0 · Δ7d 0.0
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Momentum · See technicals
Momentum
100
26% active weight
Current posture
7d trendFlat
Δ7d
-0.3
Δ21d
+0.9
Value
41
39% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
0.0
Sentiment
0
34% active weight
Current posture
7d trendFlat
Δ7d
0.0
Δ21d
0.0
Why this grade

Composite grade D. Momentum 99.6 / Value 41.1 / Sentiment 0.0

Fundamentals (TTM)
As of 2026-07-17
Market Cap
$603.4M
Beta
-0.31
Shares Out
31.53M
P/E (TTM) · Derived
-14.5
P/S (TTM)
-
P/FCF (TTM) · Derived
-24.28
Rev YoY
-
EPS YoY
-3.4%
Gross Margin
-
Op Margin
-
Net Debt
-$31.63M
Current Ratio
2.27
As of 2026-07-18 • Updated nightlySource: Internal modelMethodology